The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil

Blatyta, Paula Fraiman; Custer, Brian; Liu, Jing; Mendrone‐Júnior, Alfredo; Wright, David J.; Leão, Silvana Carneiro; Lopes, Maria Inês; Carneiro-Proietti, Anna Bárbara F.; Sabino, Éster Cerdeira; Almeida‐Neto, Cesar de

doi:10.1016/j.transci.2012.07.010

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the last years donor‐based approach had been widely introduced to reduce the risk of TRALI in the United States and Europe (Kleinman et al , ). Reduction of TRALI cases was significantly observed by the change of transfusion practice including the precautious use of plasma containing blood products derived from female donors (Chapman et al , ; Blatyta et al , ). After exclusion of female donors with a history of pregnancy or exclusion of female donors with leucocyte antibodies no case of TRALI‐induced fatality was reported (Funk et al , ).…”

mentioning

confidence: 99%

The prevalence of leucocyte alloantibodies in blood donors from South China

Xia

et al. 2015

Transfusion Medicine

View full text Add to dashboard Cite

In this study, we found alloimmunization against HLA class I, II and HNA in 4.63, 24.70 and 0.39%, respectively, in our female blood donors, indicating that the use of plasma containing blood products from parous female blood donors without HLA antibodies pre-testing may increase the risk of TRALI reaction. Although immunization against HNA seems to be a rare event in China, further observation is necessary to decide the necessity of HNA antibodies screening in our blood donors.

show abstract

mentioning

confidence: 99%

The prevalence of leucocyte alloantibodies in blood donors from South China

Xia

et al. 2015

Transfusion Medicine

View full text Add to dashboard Cite

show abstract

“…TRALI is also one of the most common adverse reactions from transfusion in Brazil. Blatyta et al estimated that the impact of deferring multiparous females as apheresis platelet donors would only decrease collections by 5%, which was considered tolerable . On the contrary, male‐only plasma and apheresis platelets would cause a much more significant reduction in products for transfusion: 31% and 24% fewer plasma and platelet units, respectively.…”

Section: Apheresis Activity In Brazil In 2013mentioning

confidence: 99%

Apheresis in developing countries around the World

Eichbaum

Smid

Crookes³

et al. 2014

J of Clinical Apheresis

View full text Add to dashboard Cite

At the combined American Society for Apheresis (ASFA) Annual Meeting/World Apheresis Association (WAA) Congress in San Francisco, California, in April of 2014, the opening session highlighted the status of apheresis outside of the United States. The organizers invited physicians active in apheresis in countries not usually represented at such international gatherings to give them a forum to share their experiences, challenges, and expectations in their respective countries with regard to both donor and therapeutic apheresis. Apheresis technology is expensive as well as technically and medically demanding, and low and median income countries have different experiences to share with the rest of the world. Apheresis procedures also require resources taken for granted in the developed world, such as reliable electrical power, that can be unpredictable in parts of the developing world. On the other hand, it was obvious that there are significant disparities in access to apheresis within the same country (such as in Brazil), as well as between neighboring nations in Africa and South America. A common trend in the presentations from Brazil, Indonesia, Malaysia, Nigeria, and South Africa, was the need for more and better physicians and practitioners' training in the indications of the various apheresis modalities and patient oversight during the procedures. As ASFA and WAA continue to work together, and globalization allows for increased knowledge-sharing, improved access to apheresis procedures performed by qualified personnel with safety and high-quality standards will be increasingly available.

show abstract

“…One of the options for Brazilian blood centers to mitigate this problem is to use male plasma only and/or to defer multiparous female donors from apheresis platelet donation. Blatyta et al analyzed the impact of only deferring multiparous females from donating apheresis platelets and found that there would be a tolerable 5% decrease of all apheresis platelet collections 9 . However, 30.8% of whole blood plasma and 24.1% of apheresis platelet donations would not be available if only male donor plasma was issued for transfusion and all female donors were deferred from apheresis donation, respectively, suggesting TRALI mitigation by selecting only male donor plasma products would have an unacceptable impact on plasma and platelet availability.…”

Section: Database Analysesmentioning

confidence: 99%

Contribution of the Retrovirus Epidemiology Donor Study (REDS) to research on blood transfusion safety in Brazil

Loureiro

Almeida‐Neto

Proietti

et al. 2014

Revista Brasileira de Hematologia e Hemoterapia

Self Cite

View full text Add to dashboard Cite

The Retrovirus Epidemiology Donor Study (REDS) program was established in the United States in 1989 with the purpose of increasing blood transfusion safety in the context of the HIV/AIDS and human T-lymphotropic virus epidemics. REDS and its successor, REDS-II were at first conducted in the US, then expanded in 2006 to include international partnerships with Brazil and China. In 2011, a third wave of REDS renamed the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) was launched. This seven-year research program focuses on both blood banking and transfusion medicine research in the United States of America, Brazil, China, and South Africa. The main goal of the international programs is to reduce and prevent the transmission of HIV/AIDS and other known and emerging infectious agents through transfusion, and to address research questions aimed at understanding global issues related to the availability of safe blood. This article describes the contribution of REDS-II to transfusion safety in Brazil. Articles published from 2010 to 2013 are summarized, including database analyses to characterize blood donors, deferral rates, and prevalence, incidence and residual risk of the main blood-borne infections. Specific studies were developed to understand donor motivation, the impact of the deferral questions, risk factors and molecular surveillance among HIV-positive donors, and the natural history of Chagas disease. The purpose of this review is to disseminate the acquired knowledge and briefly summarize the findings of the REDS-II studies conducted in Brazil as well as to introduce the scope of the REDS-III program that is now in progress and will continue through 2018.© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved.

show abstract

The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil

Cited by 5 publications

References 18 publications

The prevalence of leucocyte alloantibodies in blood donors from South China

The prevalence of leucocyte alloantibodies in blood donors from South China

Apheresis in developing countries around the World

Contribution of the Retrovirus Epidemiology Donor Study (REDS) to research on blood transfusion safety in Brazil

Contact Info

Product

Resources

About